Qiagen Closes $90M Purchase of SABiosciences, Promises 'Quick and Smooth' Integration | GenomeWeb

This article was originally posted on Dec. 14.

Qiagen said this week that it has completed its $90 million, all-cash acquisition of SABiosciences, a privately held developer of disease- and pathway-focused PCR assay panels.

Peer Schatz, CEO of Qiagen, said in a statement that he believes the integration of the 100-employee, Frederick, Md.-based company into its operations will be "a quick and smooth one," citing the "high level of complementarities" between the firms.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.